Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma von Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar

Volltext

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis von Barwick, Benjamin G., Neri, Paola, Bahlis, Nizar J., Nooka, Ajay K., Dhodapkar, Madhav V., Jaye, David L., Hofmeister, Craig C., Kaufman, Jonathan L., Gupta, Vikas A., Auclair, Daniel, Keats, Jonathan J., Lonial, Sagar, Vertino, Paula M., Boise, Lawrence H.

Volltext

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study von Bahlis, Nizar J., Dimopoulos, Meletios A., White, Darrell J., Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Krevvata, Maria, Chiu, Christopher, Qin, Xiang, Okonkwo, Linda, Trivedi, Sonali, Ukropec, Jon, Qi, Ming, San-Miguel, Jesus

Volltext

Daratumumab in multiple myeloma von Nooka, Ajay K., Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Heffner, Thomas L., Gupta, Vikas A., Sullivan, Harold C., Neish, Andrew S., Dhodapkar, Madhav V., Lonial, Sagar

Volltext

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma von Shah, Jatin J., Stadtmauer, Edward A., Abonour, Rafat, Cohen, Adam D., Bensinger, William I., Gasparetto, Cristina, Kaufman, Jonathan L., Lentzsch, Suzanne, Vogl, Dan T., Gomes, Christina L., Pascucci, Natalia, Smith, David D., Orlowski, Robert Z., Durie, BrianG.M.

Volltext

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma von Usmani, Saad Z., Nahi, Hareth, Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Chari, Ajai, Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L., Luo, Man, Liu, Kevin, San-Miguel, Jesus

Volltext

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX von Dimopoulos, Meletios A, San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L, Sutherland, Heather J, Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, H Miles, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J, Chari, Ajai, O' Rourke, Lisa, Wu, Kaida, Schecter, Jordan M, Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A Kate, Khokhar, Nushmia Z, Avet-Loiseau, Hervé, Usmani, Saad Z

Volltext

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma von LONIAL, Sagar, VIJ, Ravi, SINGHAL, Anil K, JAGANNATH, Sundar, HAROUSSEAU, Jean-Luc, FACON, Thierry, MOREAU, Philippe, MAZUMDER, Amitabha, KAUFMAN, Jonathan L, LELEU, Xavier, CLAIRE TSAO, L, WESTLAND, Christopher

Volltext

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an ope... von Kumar, Shaji K, Prof, Berdeja, Jesus G, MD, Niesvizky, Ruben, Prof, Lonial, Sagar, Prof, Laubach, Jacob P, MD, Hamadani, Mehdi, MD, Stewart, A Keith, Prof, Hari, Parameswaran, Prof, Roy, Vivek, MD, Vescio, Robert, MD, Kaufman, Jonathan L, MD, Berg, Deborah, MSN, Liao, Eileen, PhD, Di Bacco, Alessandra, PhD, Estevam, Jose, BSc, Gupta, Neeraj, PhD, Hui, Ai-Min, MD, Rajkumar, Vincent, Prof, Richardson, Paul G, Prof

Volltext

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma von Mikhael, Joseph, Richter, Joshua, Vij, Ravi, Cole, Craig, Zonder, Jeffrey, Kaufman, Jonathan L., Bensinger, William, Dimopoulos, Meletios, Lendvai, Nikoletta, Hari, Parameswaran, Ocio, Enrique M., Gasparetto, Cristina, Kumar, Shaji, Oprea, Corina, Chiron, Marielle, Brillac, Claire, Charpentier, Eric, San-Miguel, Jesús, Martin, Thomas

Volltext

The Tao of myeloma von Boise, Lawrence H., Kaufman, Jonathan L., Bahlis, Nizar J., Lonial, Sagar, Lee, Kelvin P.

Volltext

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells von Gu, Yanyan, Kaufman, Jonathan L., Bernal, Leon, Torre, Claire, Matulis, Shannon M., Harvey, R. Donald, Chen, Jing, Sun, Shi-Yong, Boise, Lawrence H., Lonial, Sagar

Volltext

Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cells von Cinar, Munevver, Martinez-Medina, Lourdes, Puvvula, Pavan K, Arakelyan, Arsen, Vardarajan, Badri N, Anthony, Neil, Nagaraju, Ganji P, Park, Dongkyoo, Feng, Lei, Sheff, Faith, Mosunjac, Marina, Saxe, Debra, Flygare, Steven, Alese, Olatunji B, Kaufman, Jonathan L, Lonial, Sagar, Sarmiento, Juan M, Lossos, Izidore S, Vertino, Paula M, Lopez, Jose A, El-Rayes, Bassel, Bernal-Mizrachi, Leon

Volltext

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evalua... von FAYAD, Luis, OFFNER, Fritz, COIFFIER, Bertrand, CZUCZMAN, Myron, GINE, Eva, DURRANT, Simon, KNEISSL, Michelle, LUU, Kenneth T, HUA, Steven Y, BONI, Joseph, VANDENDRIES, Erik, DANG, Nam H, SMITH, Mitchell R, VERHOEF, Gregor, JOHNSON, Peter, KAUFMAN, Jonathan L, ROHATINER, Ama, ADVANI, Anjali, FORAN, James, HESS, Georg

Volltext

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience von Maples, Kathryn T., Hall, Kevin H., Joseph, Nisha S., Hofmeister, Craig C., Gupta, Vikas, Dhodapkar, Madhav V., Kaufman, Jonathan L., Nooka, Ajay K., Lonial, Sagar

Volltext

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience von Scott, Sara A., Marin, Ellen M., Maples, Kathryn T., Joseph, Nisha S., Hofmeister, Craig C., Gupta, Vikas A., Dhodapkar, Madhav V., Kaufman, Jonathan L., Lonial, Sagar, Nooka, Ajay K.

Volltext

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab... von Joseph, Nisha S., Kaufman, Jonathan L., Gupta, Vilas A., Hofmeister, Craig C., Dhodapkar, Madhav V., Boise, Lawrence H., DiCamillo, Sara M., Roberts, Danielle, Nooka, Ajay K., Lonial, Sagar

Volltext

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma von Kumar, Shaji, Kaufman, Jonathan L., Gasparetto, Cristina, Mikhael, Joseph, Vij, Ravi, Pegourie, Brigitte, Benboubker, Lofti, Facon, Thierry, Amiot, Martine, Moreau, Philippe, Punnoose, Elizabeth A., Alzate, Stefanie, Dunbar, Martin, Xu, Tu, Agarwal, Suresh K., Enschede, Sari Heitner, Leverson, Joel D., Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, Touzeau, Cyrille

Volltext

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study von Jakubowiak, Andrzej J., Richardson, Paul G., Zimmerman, Todd, Alsina, Melissa, Kaufman, Jonathan L., Kandarpa, Malathi, Kraftson, Stephanie, Ross, Charles W., Harvey, Colleen, Hideshima, Teru, Sportelli, Peter, Poradosu, Enrique, Gardner, Lesa, Giusti, Kathy, Anderson, Kenneth C.

Volltext

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma von Joseph, Nisha S, Kaufman, Jonathan L, Dhodapkar, Madhav V, Hofmeister, Craig C, Almaula, Dhwani K, Heffner, Leonard T, Gupta, Vikas A, Boise, Lawrence H, Lonial, Sagar, Nooka, Ajay K

Volltext